



ITW

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Philip Ashton-Rickardt

Serial No.: 10/782,401


Filed: February 19, 2004

For: METHODS AND COMPOSITIONS FOR  
THE INHIBITION OF CATHEPSINS

Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: ARCD:390US

<b>CERTIFICATE OF MAILING</b> 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
May 12, 2004	
Date	Mark B. Wilson

**INFORMATION DISCLOSURE STATEMENT**

**MS DD**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ARCD:390US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: May 12, 2004

Form PTO-1449 (modified)

Atty. Docket No.

ARCD:390US

Serial No.

10/782,401

List of Patents and Publications for Applicant's

Applicant

Philip Ashton-Rickardt

INFORMATION DISCLOSURE STATEMENT

Filing Date:

February 19, 2004

Group:

1614

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Al-Khunaizi <i>et al.</i> , "The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases," <i>Biochemistry</i> , 41:3189-3199, 2002.
	C2	Borner and Monney, "Apoptosis without caspases: an inefficient molecular guillotine?" <i>Cell Death Diff.</i> , 6:497-507, 1999.
	C3	Cooley <i>et al.</i> , "The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites," <i>Biochemistry</i> , 40(51):15762-15770, 2001.
	C4	Ferri and Kroemer, "Organelle-specific initiation of cell death pathways," <i>Nat. Cell Biol.</i> , 3:E255-E263, 2001.
	C5	Foghsgaard <i>et al.</i> , "Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor," <i>J. Cell. Biol.</i> , 153(5):999-1009, 2001.
	C6	Goossens <i>et al.</i> , "Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity," <i>Proc. Natl. Acad. Sci., USA</i> , 92:8115-8119, 1995.
	C7	Guicciardi <i>et al.</i> , "Cathepsin B contributes to TNF- $\alpha$ -mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c," <i>J. Clin. Invest.</i> , 106(9):1127-1137, 2000.
	C8	Hampson <i>et al.</i> , "Identification of a serpin specifically expressed in multipotent and bipotent hematopoietic progenitor cells and in activated T cells," <i>Blood</i> , 89(1):108-118, 1997.

25400625.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:390US	Serial No. 10/782,401
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Philip Ashton-Rickardt	
		Filing Date: February 19, 2004	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Hampson <i>et al.</i> , "A minimal serpin promoter with high activity in haematopoietic progenitors and activated T cells," <i>Hematol. J.</i> , 2:150-160, 2001.
	C10	Inglis <i>et al.</i> , "Isolation of two cDNAs encoding novel $\alpha$ 1-antichymotrypsin-like proteins in a murine chondrocytic cell," <i>Gene</i> , 106(2):213-220, 1991.
	C11	Liu <i>et al.</i> , "NF- $\kappa$ B protects from the lysosomal pathway of cell death," <i>EMBO J.</i> , 22(19):5313-5322, 2003.
	C12	Morris <i>et al.</i> , "Murine serpin 2A is a redox-sensitive intracellular protein," <i>Biochem. J.</i> , 371(Pt 1):165-173, 2003.
	C13	Silverman <i>et al.</i> , "The serpins are an expanding superfamily of structurally similar but functionally diverse proteins," <i>J. Biol. Chem.</i> , 276(36):33293-33296, 2001.
	C14	Wyllie <i>et al.</i> , "Cell death: the significance of apoptosis," <i>Int. Rev. Cytol.</i> , 68:251-305, 1981.

25400625.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

MARK B. WILSON  
PARTNER  
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

May 12, 2004

## CERTIFICATE OF MAILING 37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

May 12, 2004

Date

Mark B. Wilson

**MS DD**

Commissioner for Patents  
P.O. Box 1450

Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/782,401 entitled "METHODS AND COMPOSITIONS FOR THE INHIBITION OF CATHEPSINS" – Philip Ashton-Rickardt*  
*Our reference: ARCD:390US*  
*Client reference: UCHI:1053*

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C14.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ARCD:390US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Mark B. Wilson  
Reg. No. 37,259

MBW/kmv  
Encl.: as noted